18F-PSMA-1007 PET/CT for Initial Staging of Renal Cell Carcinoma in an End-Stage Renal Disease Patient
Affiliations
Affiliations
- From the Sheikh Jaber Al Ahmad Al Sabah for Nuclear Medicine and Molecular Imaging Center, Kuwait City, Kuwait.
- Department of Nuclear Medicine, St Gregorios International Cancer Care Centre, Pathanamthitta, Kerala, India.
Abstract
A 46-year-old man with end-stage renal disease and renal cell carcinoma underwent F-FDG PET/CT for initial staging followed by F-PSMA-1007 PET/CT. Unlike F-FDG, which undergoes renal clearance, F-PSMA-1007 undergoes hepatobiliary clearance and thus generates superior quality images. F-PSMA-1007 PET/CT showed intense tracer-avid left renal mass lesion (FDG nonavid); lytic bone lesions (FDG avid) and single liver lesion (FDG nonavid). This case highlights the superiority of F-PSMA-1007 over F-FDG PET/CT in identifying primary lesion as well as metastatic sites in case of renal cell carcinoma even in the presence of end-stage renal disease.
Similar articles
Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.PMID: 30843003
18F-PSMA 1007 in Suspected Renal Cell Carcinoma.
Marafi F, Sasikumar A, Al-Terki A, Alfeeli M.Clin Nucl Med. 2020 May;45(5):377-378. doi: 10.1097/RLU.0000000000003002.PMID: 32209880
Sasikumar A, Joy A, Nanabala R, Unni M, Tk P.Clin Nucl Med. 2016 Dec;41(12):e517-e519. doi: 10.1097/RLU.0000000000001394.PMID: 27749421
Siva S, Callahan J, Pryor D, Martin J, Lawrentschuk N, Hofman MS.J Med Imaging Radiat Oncol. 2017 Jun;61(3):372-378. doi: 10.1111/1754-9485.12590. Epub 2017 Jan 24.PMID: 28116853 Review.
Role of Positron Emission Tomography Imaging in Metabolically Active Renal Cell Carcinoma.
Karivedu V, Jain AL, Eluvathingal TJ, Sidana A.Curr Urol Rep. 2019 Aug 29;20(10):56. doi: 10.1007/s11934-019-0932-2.PMID: 31468240 Review.
Cited by
Buller DM, Antony M, Ristau BT.Onco Targets Ther. 2023 Jan 24;16:49-64. doi: 10.2147/OTT.S393296. eCollection 2023.PMID: 36718243 Free PMC article. Review.
KMEL References
References
-
- Baccala A, Sercia L, Li J, et al. Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms. Urology. 2007;70:385–390.
-
- Demirci E, Ocak M, Kabasakal L, et al. (68)Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2014;41:1461–1462.
-
- Rhee H, Blazak J, Tham CM, et al. Pilot study: use of gallium-68 PSMA PET for detection of metastatic lesions in patients with renal tumour. EJNMMI Res. 2016;6:76.
-
- Sawicki LM, Buchbender C, Boos J, et al. Diagnostic potential of PET/CT using a 68Ga-labelled prostate-specific membrane antigen ligand in whole-body staging of renal cell carcinoma: initial experience. Eur J Nucl Med Mol Imaging. 2017;44:102–107.
-
- Siva S, Callahan J, Pryor D, et al. Utility of 68Ga prostate specific membrane antigen–positron emission tomography in diagnosis and response assessment of recurrent renal cell carcinoma. J Med Imaging Radiat Oncol. 2017;61:372–378.
-
- Sasikumar A, Joy A, Nanabala R, et al. Complimentary pattern of uptake in 18F-FDG PET/CT and 68Ga-prostate-specific membrane antigen PET/CT in a case of metastatic clear cell renal carcinoma. Clin Nucl Med. 2016;41:e517–e519.
-
- Marafi F, Sasikumar A, Al-Terki A, et al. 18F-PSMA 1007 in suspected renal cell carcinoma. Clin Nucl Med. 2020;45:377–378.
-
- Pianou NK, Stavrou PZ, Vlontzou E, et al. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT. Hell J Nucl Med. 2019;22:6–9.
-
- Lawal IO, Popoola GO, Lengana T, et al. Diagnostic utility of 18F-FDG PET/CT in fever of unknown origin among patients with end-stage renal disease treated with renal replacement therapy. Hell J Nucl Med. 2019;22:70–75.